ANNOUNCER: However, today, the non- steroidals give doctors a new element to factor into the decision on which treatment to use for each patient.
SHEILA FRIEDLANDER, MD: If I need to use something for a prolonged period for my patient, I will use one of the new immunomodulators, on the face, particularly. I think it's a real gain for us to have an agent that we can use chronically that does not seem to have the risks of atrophy, thinning of the skin or cataracts. So, particularly around the eyelids, on the face, I will use the newer immunomodulators.
A. PAUL KELLY, MD: You think about the nonsteroidals with the age of the patient, the location of the lesions; if it's facial, if it's under the arms, if it's between the legs, if it's on the genitalia, then you would probably go with a nonsteroidal.
If it's recurrent, because they're taking their steroids and not getting better, then you would definitely think about them.
ANNOUNCER: Having new non steroidal options is particularly good news for children and their parents.
SHEILA FRIEDLANDER, MD: There has been some new data that's come out with the newer immunomodulators, particularly with Elidel, and it has been found that it was very, very efficacious, very useful in preventing flare. And the absorption of the drug was minimal. So this is certainly an option that you can use with young children.
ANNOUNCER: While eczema treatments are not cures, having a variety of options means people can have a broader range of safe and effective therapies to treat their condition.